Cytokinetics (CYTK)
NASDAQ:CYTK

Cytokinetics Stock Price & Analysis

599 Followers

CYTK Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$29.26 - $55.80
Previous Close$37.04
Volume1.29M
Average Volume (3M)1.09M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$867.66M
Total Debt (Recent Filing)$738.99M
Price to Earnings (P/E)-11.7
Beta0.37
Next EarningsFeb 23, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-3.16
Shares Outstanding94,631,001
R-Squared0.11
Standard Deviation0.16
10 Day Avg. Volume918,173
30 Day Avg. Volume1,092,262
Price to Book (P/B)-225.78
Price to Sales (P/S)23.62
Price to Cash Flow (P/CF)409.20
P/FCF Ratio-13.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside103.56% Upside
Rating ConsensusStrong Buy
Alpha0.03
Number of Analyst Covering5


Financials


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CYTK FAQ

What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $29.26 and its highest was $55.80 in the past 12 months.
    What is Cytokinetics’s market cap?
    Currently, no data Available
    When is Cytokinetics’s upcoming earnings report date?
    Cytokinetics’s upcoming earnings report date is Feb 23, 2023 which is in 77 days.
      How were Cytokinetics’s earnings last quarter?
      Cytokinetics released its earnings results on Nov 03, 2022. The company reported -$1.52 earnings per share for the quarter, missing the consensus estimate of -$1.164 by -$0.356.
        Is Cytokinetics overvalued?
        According to Wall Street analysts Cytokinetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Cytokinetics pay dividends?
          Cytokinetics does not currently pay dividends.
          What is Cytokinetics’s EPS estimate?
          Cytokinetics’s EPS estimate is -$1.21.
            How many shares outstanding does Cytokinetics have?
            Cytokinetics has 94,631,004 shares outstanding.
              What happened to Cytokinetics’s price movement after its last earnings report?
              Cytokinetics reported an EPS of -$1.52 in its last earnings report, missing expectations of -$1.164. Following the earnings report the stock price went down -5.031%.
                Which hedge fund is a major shareholder of Cytokinetics?
                Among the largest hedge funds holding Cytokinetics’s share is Farallon Capital Management, L.L.C.. It holds Cytokinetics’s shares valued at 79M.

                  ---

                  Cytokinetics Stock Smart Score

                  The Cytokinetics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Cytokinetics

                  Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Denali Therapeutics
                  Natera
                  Intellia Therapeutics
                  Cerevel Therapeutics Holdings

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis